↓ Skip to main content

Heart Failure

Overview of attention for book
Cover of 'Heart Failure'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 13 Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction
  3. Altmetric Badge
    Chapter 23 Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications
  4. Altmetric Badge
    Chapter 24 Heart Failure Guidelines on Pharmacotherapy
  5. Altmetric Badge
    Chapter 25 Role of Hyperkalemia in Heart Failure and the Therapeutic Use of Potassium Binders
  6. Altmetric Badge
    Chapter 27 Comorbidities in Heart Failure
  7. Altmetric Badge
    Chapter 28 Vasopressin and Vasopressin Antagonists in Heart Failure
  8. Altmetric Badge
    Chapter 30 Iron Deficiency Treatment in Patients with Heart Failure
  9. Altmetric Badge
    Chapter 31 Cardiac Myosin Activation with Gene Therapy Produces Sustained Inotropic Effects and May Treat Heart Failure with Reduced Ejection Fraction
  10. Altmetric Badge
    Chapter 55 Ivabradine.
  11. Altmetric Badge
    Chapter 56 Wnt Signaling in Cardiac Remodeling and Heart Failure
  12. Altmetric Badge
    Chapter 74 Epidemiology of Heart Failure
  13. Altmetric Badge
    Chapter 75 Clinical Trial Design, Endpoints, and Regulatory Requirements
  14. Altmetric Badge
    Chapter 76 Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside
  15. Altmetric Badge
    Chapter 77 Sacubitril/Valsartan (LCZ696) in Heart Failure
  16. Altmetric Badge
    Chapter 80 Platelet-Derived Growth Factor in Heart Failure
  17. Altmetric Badge
    Chapter 81 Gene Therapy in Heart Failure
  18. Altmetric Badge
    Chapter 82 Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
  19. Altmetric Badge
    Chapter 83 Partial Adenosine A1 Agonist in Heart Failure
  20. Altmetric Badge
    Chapter 86 Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction
  21. Altmetric Badge
    Chapter 88 New and Emerging Therapies and Targets: Beta-3 Agonists
  22. Altmetric Badge
    Chapter 99 Noncoding RNAs in Heart Failure
  23. Altmetric Badge
    Chapter 100 Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure
  24. Altmetric Badge
    Chapter 101 The Three-Decade Long Journey in Heart Failure Drug Development
  25. Altmetric Badge
    Chapter 123 Mitochondrial Therapies in Heart Failure
  26. Altmetric Badge
    Chapter 126 Anticoagulation Therapy and NOACs in Heart Failure
Attention for Chapter 82: Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news
1 news outlet
twitter
1 X user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
69 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease
Chapter number 82
Book title
Heart Failure
Published in
Handbook of experimental pharmacology, January 2016
DOI 10.1007/164_2016_82
Pubmed ID
Book ISBNs
978-3-31-959658-7, 978-3-31-959659-4
Authors

Kim, Grace E., Kass, David A., Grace E. Kim, David A. Kass

Abstract

An important hallmark of cardiac failure is abnormal second messenger signaling due to impaired synthesis and catabolism of cyclic adenosine 3',5'- monophosphate (cAMP) and cyclic guanosine 3',5'- monophosphate (cGMP). Their dysregulation, altered intracellular targeting, and blunted responsiveness to stimulating pathways all contribute to pathological remodeling, muscle dysfunction, reduced cell survival and metabolism, and other abnormalities. Therapeutic enhancement of either cyclic nucleotides can be achieved by stimulating their synthesis and/or by suppressing members of the family of cyclic nucleotide phosphodiesterases (PDEs). The heart expresses seven of the eleven major PDE subtypes - PDE1, 2, 3, 4, 5, 8, and 9. Their differential control over cAMP and cGMP signaling in various cell types, including cardiomyocytes, provides intriguing therapeutic opportunities to counter heart disease. This review examines the roles of these PDEs in the failing and hypertrophied heart and summarizes experimental and clinical data that have explored the utility of targeted PDE inhibition.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 69 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 14%
Student > Bachelor 10 14%
Researcher 7 10%
Student > Master 5 7%
Student > Doctoral Student 4 6%
Other 6 9%
Unknown 27 39%
Readers by discipline Count As %
Medicine and Dentistry 12 17%
Biochemistry, Genetics and Molecular Biology 10 14%
Pharmacology, Toxicology and Pharmaceutical Science 10 14%
Agricultural and Biological Sciences 4 6%
Nursing and Health Professions 1 1%
Other 4 6%
Unknown 28 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2019.
All research outputs
#3,160,429
of 23,043,346 outputs
Outputs from Handbook of experimental pharmacology
#107
of 647 outputs
Outputs of similar age
#56,795
of 394,754 outputs
Outputs of similar age from Handbook of experimental pharmacology
#9
of 55 outputs
Altmetric has tracked 23,043,346 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 647 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.4. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 394,754 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.